Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis

Human Psychopharmacology

Volumn , Issue , 2016, Pages 286-295

  Zheng, Wei ^a   Xiang, Ying Qiang ^b,c,d   Li, Xian Bin ^b,c,d   Ungvari, Gabor S ^e   Chiu, Helen F K ^f   Sun, Feng ^g   D’Arcy, Carl ^h   Meng, Xiangfei ⁱ   Xiang, Yu Tao ^j  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b NATIONAL CLINICAL RESEARCH CENTER FOR GERIATRIC DISORDERS   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^h UNIVERSITY OF SASKATCHEWAN   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j University of Macau   (Macao)

more..

Author keywords

antipsychotic; cognitive function; huperzine A; meta analysis; schizophrenic spectrum disorders; systematic review

Indexed keywords

HUPERZINE A; LIVER ENZYME; PLACEBO;

AGITATION; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CHINA; COGNITION; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ECG ABNORMALITY; ENZYME BLOOD LEVEL; EXCITEMENT; HUMAN; INSOMNIA; INTELLIGENCE QUOTIENT; META ANALYSIS; MUSCLE RIGIDITY; NAUSEA AND VOMITING; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; WECHSLER ADULT INTELLIGENCE SCALE; WECHSLER MEMORY SCALE; WEIGHT GAIN; WISCONSIN CARD SORTING TEST;

EID: 84977619161     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2537     Document Type: Article

References (49)

1. Buchanan RW, Conley RR, Dickinson D, et al. 2008. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165: 82–89.
2. Chen FX. 2007. The effects of huperzine A as add-on therapy in patients with chronic schizophrenia [in Chinese]. Mod Pract Med 19: 370–371.
3. Chen XH, Xia XB, Wang LH. 2011. A comparative study of huperzine on cognitive dysfunction in patients with schizophrenia [in Chinese]. Med J Chin People's Health 23: 2915–2918.
4. Chen Y-F. 2002. Chinese classification of mental disorders (CCMD-3): towards integration in international classification. Psychopathology 35: 171–175.
5. Choi KH, Wykes T, Kurtz MM. 2013. Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br J Psychiatry J Ment Sci 203: 172–178.
6. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
7. Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
8. Fang CX, Gou CR, Wu B, Jing YT. 2002. The effects of huperzine A on cognitive function in patients with schizophrenia [in Chinese]. Shandong Arch Psyc 15: 39–40.
9. Ferreri F, Agbokou C, Gauthier S. 2006. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 31: 369–376.
10. Flaum M, Andreasen NC. 1991. Diagnostic criteria for schizophrenia and related disorders: options for DSM-IV. Schizophr Bull 17: 133–142.
11. Folstein MF, Folstein SE, McHugh PR. 1975. Mini-mental state A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.
12. Francis PT, Palmer AM, Snape M, Wilcock GK. 1999. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137–147.
13. Friedman JI, Adler DN, Howanitz E, et al. 2002. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51: 349–357.
14. Furlan AD, Pennick V, Bombardier C, van Tulder M. 2009. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 34: 1929–1941.
15. Giacobini E. 1998. Invited review Cholinesterase Inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 32: 413–419.
16. Gong Y. 1992. Wechsler Adult Intelligence Scale-revised in China Version. Hunan Medical College: Changsha, Hunan/China.
17. Gong Y, Jiang D, Deng J, Dai Z, Zhou Q. 1989. Wechsler Memory Scale-revised manual (Chinese Version). Hunan Med University. Changsha, China: 2–10.
18. Heaton R, Chelune G, Talley J, Kay G, Curtiss G. 1981. Wisconsin Card Sorting Test manual. Psychological Assessment Resources. Inc.: Odessa, Florida.
19. Higgins JP, Green S. 2008. Cochrane handbook for systematic reviews of interventions: Wiley Online Library.
20. Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.
21. Huang CH, Deng XM, Yang ZB. 2007. A comparative study of efficacy of Huperzine-A in the treatment of memory dysfunction of schizophrenia [in Chinese]. Sichuan Ment Health 20: 69–70.
22. Jadad AR, Moore RA, Carroll D, et al. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
23. Jakobsen KD, Frederiksen JN, Hansen T, Jansson LB, Parnas JTW. 2005. Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiat 59: 209–212.
24. Jie Y, Wang ZW, Liu RS, Wang YG. 2012. Effects of Huperzine a combined with risperidone on cognitive function in chronic schizophrenic patients [in Chinese]. J Psychiat 25: 191–194.
25. Kay SR, Flszbein A, Opfer LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261.
26. Ma JD, Zheng H, Wang YJ. 2003. Effect of hyberzine on the memory disoders of schizophrenic patient during rehabilitation period [in Chinese]. Heath Psychol J 11: 340–341.
27. Ma X, Tan C, Zhu D, Gang DR, Xiao P. 2007. Huperzine A from Huperzia species – an ethnopharmacolgical review. J Ethnopharmacol 113: 15–34.
28. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O. 2002. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110: 627–639.
29. Moher D, Liberati A, Tetzlaff J, Altman DG. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264–269 W264.
30. Overall JE, Beller SA. 1984. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I Factor structure on an inpatient unit. J Gerontol 39: 187–193.
31. Patel SS, Attard A, Jacobsen P, Shergill S. 2010a. Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report. BMC Psychiat 10: 68.
32. Patel SS. 2010b. Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature. BMC Psychiat 10: 69.
33. Reitan RM, Wolfson D. 1985. The Halstead–Reitan neuropsychological test battery: theory and clinical interpretation: Reitan Neuropsychology.
34. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. 2010. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24: 303–317.
35. Sharma T, Reed C, Aasen I, Kumari V. 2006. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 85: 73–83.
36. Song ZH, Shi SH, Sheng ZH. 2007. Clinical efficacy of hyperzine on cognitive function of schizophrenia [in Chinese]. Shanghai Arch Psychiat 19: 277–279.
37. Tao JM. 2012. Clinical observation of quetiapine combined with huperzine A in the treatment of memory dysfunction of patients with schizophrenia [in Chinese]. China Mod Med 19: 57–58.
38. Trikalinos TA, Churchill R, Ferri M, et al. 2004. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 57: 1124–1130.
39. Voss B, Thienel R, Leucht S, Kircher T. 2008. Therapy of cognitive deficits in schizophrenia with acetylcholinesterase inhibitors. A systematic overview. Nervenarzt 79: 47–48 50-42, 54-49.
40. Wang DM, Li BQ, Li LQ. 2007. The study of huperzine on cognitive function in the treatment of patients with chronic schizophrenia [in Chinese]. Journal of Baotou Medical College 23: 18–19.
41. Wang R, Yan H, Tang XC. 2006. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 27: 1–26.
42. Wang ZY, Zhang L. 2004. Effects of huperzine A combined with risperidone on cognitive function in chronic schizophrenic patients [in Chinese]. J Clin Psychol Med 14: 280–281.
43. Weinberger DR, Gallhofer B. 1997. Cognitive function in schizophrenia. Int Clin Psychopharmacol 12(Suppl 4): S29–36.
44. Wu GW, Zhang CZ. 2015. Influences of olanzapine combined with huperzine A on memory function of convalescence schizophrenia patient [in Chinese]. J Clin Psychosom Dis 21: 41–43 56.
45. Xing SH, Zhu CX, Zhang R, An L. 2014. Huperzine A in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis. eCAM 2014: 363985.
46. Xu SL. 1984. Clinical Memory Scale Manual [In Chinese]. the Institute of Psychology of Chinese Academy of Sciences Beijing, China 6.
47. Zhang HY, Tang XC. 2006. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27: 619–625.
48. Zhang SX. 2012. Effect of adjunctive huperzine on cognitive function in schizophrenia [in Chinese]. Medical Innovation of China 9: 6–7.
49. Zhang ZJ, Tong Y, Wang XY, Yao SM, Jin GX, Wang XP. 2007. Huperzine A as add-on therapy in patients with treatment-resistant schizophrenia: an open-labeled trial. Schizophr Res 92: 273–275.